Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication

Figure 1 Cumulative incidence of hepatocellular carcinoma development after sustained virological response. HCC: Hepatocellular carcinoma.

Figure 2 Representative AKR1B10 immunohistochemical staining of specimens. Normal liver tissue (A, B) and tissue from patients with chronic hepatitis C (C-F). Hematoxylin and eosin staining (A, C, E) and AKR1B10 immunostaining (B, D, F). Positive control, bile-duct epithelium; original magnification × 40.

Figure 3 Distribution of AKR1B10 expression levels in the study cohort. Filled and blank patterns indicate patients with and without hepatocellular carcinoma development, respectively.

Figure 4 Cumulative incidence of hepatocellular carcinoma development after sustained virological response, shown according to AKR1B10 expression level.

Figure 5 Relationships between baseline AKR1B10 expression levels and alanine aminotransferase and α-fetoprotein levels after sustained virological response. ¹Mann-Whitney U test. EOT: End of treatment.